Clinical trials · Chicago, IL
Cancer clinical trials in Chicago
We’re tracking 619 recruiting cancer studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Chicago, IllinoisAges 18 years+ - NCT07044336RecruitingPhase 3
Comparing a new drug to chemo for advanced endometrial cancer
This trial tests a new investigational drug called Puxitatug Samrotecan (AZD8205) against standard chemotherapy in people whose endometrial cancer has come back or spread after prior treatment with platinum chemo and an immunotherapy. The goal is to see if the new drug works better.
Chicago, IllinoisAges 18 years+ - NCT05526924RecruitingPhase 1
Phase 1 trial tests re-radiation plus immunotherapy and a cancer pill
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
Chicago, IllinoisAges 18 years+ - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Chicago, IllinoisAges 35 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Chicago, IllinoisAges Up to 21 years - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Chicago, IllinoisAges 18 years+ - NCT05537922Recruiting
Study uses data to tailor lung cancer care with immunotherapy
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Chicago, IllinoisAges 18 years+ - NCT05999994RecruitingPhase 2
Testing new drugs for children and young adults with cancer
This trial tests several experimental drugs for children and young adults with cancer. It aims to find safe and effective treatments by matching participants to one of several drug studies based on their cancer type and health.
Chicago, IllinoisAges 1–39 - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Chicago, IllinoisAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT07023289RecruitingPhase 2
Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Chicago, IllinoisAges 18 years+ - NCT07603856RecruitingPhase 2
Combining Immunotherapy and Radiation for Advanced Lung Cancer
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
Chicago, IllinoisAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Chicago, IllinoisAges 18–100 - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT06022822RecruitingPhase 2
Urolithin A supplement before prostate cancer surgery
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Chicago, IllinoisAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Chicago, IllinoisAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Chicago, IllinoisAges 5–60 - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Chicago, IllinoisAges 18 years+ - NCT07057791RecruitingPhase 2
Chemo plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Chicago, IllinoisAges 18 years+ - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Chicago, IllinoisAges 18–59 - NCT05710380Recruiting
MRI scans to guide biopsy for prostate cancer diagnosis
This study tests whether special MRI “risk maps” can help doctors better identify suspicious areas in the prostate during diagnosis. If you’re having an MRI followed by an MRI-guided biopsy, this may help improve how the biopsy targets areas of concern.
Chicago, IllinoisAges 18 years+ - NCT05726292RecruitingPhase 2
Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Chicago, IllinoisAges 18 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Chicago, IllinoisAges 18 years+ - NCT05612347Recruiting
Compare stool test vs colonoscopy for older adults with polyps
This study compares two ways to check for colon polyps in older adults: using a stool test versus having a colonoscopy. It may help find a simpler option if you only had a small number of lower-risk polyps before.
Chicago, IllinoisAges 65–82
Hear when a new Cancer trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting cancer studies listed above.
- Northwestern University · 10 studies
- University of Chicago Comprehensive Cancer Center · 5 studies
- University of Chicago Medical Center · 4 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 3 studies
- NorthShore University HealthSystem-Evanston Hospital · 3 studies
- Loyola University Medical Center · 2 studies
- NorthShore University HealthSystem-Glenbrook Hospital · 2 studies
- NorthShore University HealthSystem-Highland Park Hospital · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Illinois.
Common questions
- Are there cancer clinical trials near Chicago?
- Yes. We're currently tracking 619 recruiting cancer studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.